[go: up one dir, main page]

EA201500316A1 - Антагонисты толл-подобного рецептора 3 - Google Patents

Антагонисты толл-подобного рецептора 3

Info

Publication number
EA201500316A1
EA201500316A1 EA201500316A EA201500316A EA201500316A1 EA 201500316 A1 EA201500316 A1 EA 201500316A1 EA 201500316 A EA201500316 A EA 201500316A EA 201500316 A EA201500316 A EA 201500316A EA 201500316 A1 EA201500316 A1 EA 201500316A1
Authority
EA
Eurasian Patent Office
Prior art keywords
toll
receptor
antagonists
tlr3
antagonist antibodies
Prior art date
Application number
EA201500316A
Other languages
English (en)
Inventor
Марк Каннингхэм
Лани Сан Матео
Роберт Т. Сариски
Рэймонд Свит
Роберт Раухенбергер
Марк Рутц
Ицин Фэн
Катарина Херинга
Цзиньцюань Ло
Фан Тэн
Алексей Тепляков
Шэн-Дзюн Ву
Original Assignee
Сентокор Орто Байотек Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор Орто Байотек Инк. filed Critical Сентокор Орто Байотек Инк.
Publication of EA201500316A1 publication Critical patent/EA201500316A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)

Abstract

Описываются антитела-антагонисты толл-подобного рецептора 3 (TLR3), полинуклеотиды, кодирующие антитела-антагонисты TLR3 или их фрагменты, и способы изготовления и применения вышеуказанных веществ.
EA201500316A 2008-10-31 2009-10-30 Антагонисты толл-подобного рецептора 3 EA201500316A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10997408P 2008-10-31 2008-10-31
US16186009P 2009-03-20 2009-03-20
US16510009P 2009-03-31 2009-03-31
US17368609P 2009-04-29 2009-04-29

Publications (1)

Publication Number Publication Date
EA201500316A1 true EA201500316A1 (ru) 2016-01-29

Family

ID=42129569

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201500316A EA201500316A1 (ru) 2008-10-31 2009-10-30 Антагонисты толл-подобного рецептора 3
EA201170636A EA022832B1 (ru) 2008-10-31 2009-10-30 Выделенное антитело, способное взаимодействовать с tlr3

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201170636A EA022832B1 (ru) 2008-10-31 2009-10-30 Выделенное антитело, способное взаимодействовать с tlr3

Country Status (33)

Country Link
US (8) US8409567B2 (ru)
EP (1) EP2350304B1 (ru)
JP (1) JP5751631B2 (ru)
KR (1) KR101683033B1 (ru)
CN (2) CN102300997B (ru)
AU (1) AU2009308763B2 (ru)
BR (1) BRPI0921696A2 (ru)
CA (1) CA2742014A1 (ru)
CL (1) CL2011000975A1 (ru)
CO (1) CO6362052A2 (ru)
CY (1) CY1118797T1 (ru)
DK (1) DK2350304T3 (ru)
EA (2) EA201500316A1 (ru)
EC (1) ECSP11011072A (ru)
ES (1) ES2618567T3 (ru)
HK (1) HK1166105A1 (ru)
HR (1) HRP20170415T1 (ru)
HU (1) HUE031756T2 (ru)
IL (1) IL212545A (ru)
LT (1) LT2350304T (ru)
MX (1) MX2011004635A (ru)
MY (1) MY183144A (ru)
NI (1) NI201100085A (ru)
NZ (2) NZ592542A (ru)
PE (1) PE20110808A1 (ru)
PL (1) PL2350304T3 (ru)
PT (1) PT2350304T (ru)
RS (1) RS55861B1 (ru)
SI (1) SI2350304T1 (ru)
SM (2) SMT201700127T1 (ru)
SV (1) SV2011003891A (ru)
UA (1) UA109397C2 (ru)
WO (1) WO2010051470A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
JP5751631B2 (ja) 2008-10-31 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド Ｔｏｌｌ様受容体３アンタゴニスト
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
DK2425008T3 (en) * 2009-04-29 2015-10-05 Janssen Biotech Inc Toll-like receptor antagonists 3
ES2543095T3 (es) 2009-07-10 2015-08-14 Innate Pharma Agentes de unión a TLR3
EP2663329A2 (en) 2011-01-12 2013-11-20 Innate Pharma Tlr3 binding agents
EA201490623A1 (ru) * 2011-09-12 2016-01-29 Янссен Байотек Инк. Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний
WO2013178736A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
EP3560960A1 (en) * 2013-04-22 2019-10-30 The University of Tokyo Preventive or therapeutic agent for inflammatory disease
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015016282A1 (ja) * 2013-07-30 2015-02-05 国立大学法人東京大学 放射線誘導性消化管症候群の予防又は治療用医薬組成物
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
US10429214B2 (en) * 2017-03-07 2019-10-01 Newtonoid Technologies, L.L.C. Modular elongated wall-mounted sensor system and method
CN109136231B (zh) * 2018-09-14 2019-08-30 苏州大学 一种翘嘴鳜tlr3基因及其应用
AU2023279086A1 (en) * 2022-05-31 2025-01-16 The University Of Chicago Chemical screen of modulators for vaccine adjuvants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1451581A4 (en) * 2001-10-05 2006-01-11 Coley Pharm Gmbh AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3
JP2004016021A (ja) * 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
KR20060016817A (ko) * 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 소분자 톨-유사 수용체 (ｔｌｒ) 길항제
CA2483732A1 (en) 2004-09-29 2006-03-29 Ronan Le Goffic Toll-like receptor 3, its signalling associated molecule trif and their use thereof
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
TWI487535B (zh) * 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
JP5199878B2 (ja) 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
AU2008223446B2 (en) * 2007-03-05 2012-02-02 Utah State University Restrictive agonist of Toll-like receptor 3 (TLR3)
US20080299138A1 (en) * 2007-05-25 2008-12-04 Duffy Karen E Toll-Like Receptor 3 Modulators and Uses Thereof
WO2010031749A1 (en) * 2008-09-17 2010-03-25 Innate Pharma Compositions and methods for detecting tlr3
EP2344175B1 (en) * 2008-10-02 2015-07-22 Janssen Biotech, Inc. Methods for suppressing toll-like receptor activity
JP5751631B2 (ja) 2008-10-31 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド Ｔｏｌｌ様受容体３アンタゴニスト
US20100188778A1 (en) * 2009-01-29 2010-07-29 Castagna Joseph T Disk Drive Assembly Having Flexible Support for Flexible Printed Circuit Board
DK2425008T3 (en) 2009-04-29 2015-10-05 Janssen Biotech Inc Toll-like receptor antagonists 3
ES2543095T3 (es) * 2009-07-10 2015-08-14 Innate Pharma Agentes de unión a TLR3

Also Published As

Publication number Publication date
MX2011004635A (es) 2011-07-19
US20180179294A1 (en) 2018-06-28
IL212545A (en) 2014-07-31
KR101683033B1 (ko) 2016-12-06
PT2350304T (pt) 2017-03-23
AU2009308763A1 (en) 2010-05-06
SV2011003891A (es) 2011-07-21
DK2350304T3 (en) 2017-03-13
NI201100085A (es) 2011-11-21
EA201170636A1 (ru) 2012-03-30
MY183144A (en) 2021-02-16
EP2350304B1 (en) 2016-12-14
CN105601742A (zh) 2016-05-25
US20130280263A1 (en) 2013-10-24
KR20110081874A (ko) 2011-07-14
US20140093508A1 (en) 2014-04-03
LT2350304T (lt) 2017-02-10
SMT201700127B (it) 2017-03-08
US9932404B2 (en) 2018-04-03
ES2618567T3 (es) 2017-06-21
BRPI0921696A2 (pt) 2015-08-18
US20140212426A1 (en) 2014-07-31
UA109397C2 (uk) 2015-08-25
EA022832B1 (ru) 2016-03-31
US9238693B2 (en) 2016-01-19
EP2350304A4 (en) 2014-04-16
HK1166105A1 (zh) 2012-10-19
CA2742014A1 (en) 2010-05-06
PE20110808A1 (es) 2011-10-31
NZ592542A (en) 2013-01-25
US8540986B2 (en) 2013-09-24
SMT201700127T1 (it) 2017-03-08
PL2350304T3 (pl) 2017-06-30
WO2010051470A2 (en) 2010-05-06
US20130244281A1 (en) 2013-09-19
CL2011000975A1 (es) 2012-02-03
HRP20170415T1 (hr) 2017-05-05
CY1118797T1 (el) 2017-07-12
US20100166778A1 (en) 2010-07-01
HUE031756T2 (en) 2017-07-28
CO6362052A2 (es) 2012-01-20
US9255153B2 (en) 2016-02-09
ECSP11011072A (es) 2011-06-30
NZ603824A (en) 2013-11-29
EP2350304A2 (en) 2011-08-03
CN102300997A (zh) 2011-12-28
CN102300997B (zh) 2016-01-20
US9481731B2 (en) 2016-11-01
AU2009308763B2 (en) 2017-03-09
US20110008352A1 (en) 2011-01-13
US20170058041A1 (en) 2017-03-02
JP2012507564A (ja) 2012-03-29
SI2350304T1 (sl) 2017-04-26
US9522957B2 (en) 2016-12-20
RS55861B1 (sr) 2017-08-31
US8409567B2 (en) 2013-04-02
JP5751631B2 (ja) 2015-07-22
IL212545A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
EA201170636A1 (ru) Антагонисты толл-подобного рецептора 3
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
EA201290254A1 (ru) Антагонисты il-17a
CU20120095A7 (es) Antagonistas de pcsk9
EA200870409A1 (ru) Антагонисты киназы pi3
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
MA34520B1 (fr) Anticorps se liant à la myostatine, compositions et procédés
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
MY156315A (en) Anti-vegf antibodies
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
EA201100868A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин
EA200701979A1 (ru) Способ получения опиоидных модуляторов
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
CY1111811T1 (el) Μεθοδοι ms για την αξιολογηση γλυκανων
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
EA200900767A1 (ru) Антагонистические антитела против ephb3
EA201490623A1 (ru) Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний
CY1117024T1 (el) Ανταγωνιστες του υποδοχεα 3 τυπου toll